How RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’

With China accounting for an ever-larger share of global drug R&D innovation, RA Capital wants to make sure its portfolio biotechs aren't missing out. Rather than leave the work of developing relationships in China to individual companies, the firm launched an initiative called RA Capital Swiftbridge in mid-2025. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events…

Source: FierceBiotech